GoldenGolden
Advanced Search
Impel NeuroPharma

Impel NeuroPharma

Impel NeuroPharma is an olfactory Delivery device.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

December 7, 2018
Impel NeuroPharma raises a $67,500,000 series D round from KKR.
December 2018
Impel NeuroPharma raises a $67,500,000 series D round from 5AM Ventures, KKR, Norwest Venture Partners, Vivo Capital and venBio.
December 2, 2016
Impel NeuroPharma raises a $36,000,000 series C round from venBio.

Funding rounds

SBA Awards

People

Name
Role
LinkedIn

Chris Fuller

Employee

Gregg Bennett

Investor

Michael Hite

Employee

Paula Kim

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 18, 2021
BioSpace
Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.
Impel NeuroPharma
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) for INP104...
June 10, 2020
BioSpace
Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine - read this article along with other careers information, tips and advice on BioSpace
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.